Skip to main content
    T

    Transcode Therapeutics Inc (RNAZ)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.35
    +0.03 (+2.27%)

    Market Cap: $22.35M

    Last updated: Nov 17, 2026 at 11:02 AM ET

    Transcode Therapeutics Inc (RNAZ) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Transcode Therapeutics are Plus Therapeutics (PSTV), Context Therapeutics (CNTX) and Telomir Pharmaceuticals, Inc. Common Stock (TELO). By market cap, Transcode Therapeutics ranks 7th of the 13 companies on this page; Grace Therapeutics (GRCE) is the largest at $38.08M.

    Peer Comparison

    RNAZ's ROIC of -412.7% is below the peer median of -129.7%, and its revenue growth of 0.0% is above the median of -1.4%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Transcode Therapeutics (RNAZ)$22.35MN/AN/A0.0%-412.7%0.0%0.00%
    Plus Therapeutics Inc (PSTV)$26.64MN/A2.0x-230.2%-827.8%-2.9%0.00%
    Context Therapeutics Inc (CNTX)$16.61MN/AN/A0.0%N/A0.0%0.00%
    Telomir Pharmaceuticals, Inc. Common Stock (TELO)$36.15MN/AN/A0.0%N/A0.0%0.00%
    Tvardi Therapeutics, Inc. (TVRD)$15.74MN/AN/A0.0%N/A0.0%0.00%
    Marker Therapeutics Inc (MRKR)$14.51MN/A14.5x-245.5%N/A-51.0%0.00%
    Tscan Therapeutics Inc (TCRX)$10.89MN/A3.6x0.0%-129.7%-65.8%0.00%
    Cyclerion Therapeutics Inc (CYCN)$15.73MN/AN/A0.0%N/A-43.2%0.00%
    NextCure Inc (NXTC)$29.31MN/AN/A0.0%N/A-100.0%0.00%
    Cocrystal Pharma Inc (COCP)$18.88MN/A39.2x0.0%N/A26.9%0.00%
    CervoMed Inc. (CRVO)$25.57MN/AN/A0.0%N/A-99.6%0.00%
    Grace Therapeutics, Inc. (GRCE)$38.08MN/AN/A0.0%N/A0.0%0.00%
    Pelthos Therapeutics Inc. (PTHS)$29.24MN/A0.5x-199.5%-95.4%0.0%0.00%
    Peer median$22.22MN/A3.6x0.0%-129.7%-1.4%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Transcode Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Plus Therapeutics Inc (PSTV)
    Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacturing...
    PSTV competitors
    Context Therapeutics Inc (CNTX)
    Centrexion Therapeutics Corporation, a late-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel, non-opioid...
    CNTX competitors
    Telomir Pharmaceuticals, Inc. Common Stock (TELO)
    Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human...
    TELO competitors
    Tvardi Therapeutics, Inc. (TVRD)
    Tvardi Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company focused on developing novel oncology therapies to meet critical unmet...
    TVRD competitors
    Marker Therapeutics Inc (MRKR)
    Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based...
    MRKR competitors
    Tscan Therapeutics Inc (TCRX)
    Tscan Therapeutics Inc (TCRX) is a pioneering clinical-stage biotechnology company specializing in precision oncology through its proprietary T cell receptor...
    TCRX competitors
    Cyclerion Therapeutics Inc (CYCN)
    Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development...
    NextCure Inc (NXTC)
    NextCure, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of novel immunomedicines to treat cancer and other...
    NXTC competitors
    Cocrystal Pharma Inc (COCP)
    Cocrystal Pharma, Inc., a biotechnology company, is focused on the discovery and development of antiviral therapeutic treatments for serious and / or chronic...
    COCP competitors
    CervoMed Inc. (CRVO)
    CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases.
    CRVO competitors
    Grace Therapeutics, Inc. (GRCE)
    Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
    GRCE competitors
    Pelthos Therapeutics Inc. (PTHS)
    Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
    PTHS competitors

    Frequently Asked Questions About RNAZ

    Who are Transcode Therapeutics' main competitors?

    The companies most similar to Transcode Therapeutics include Plus Therapeutics (PSTV), Context Therapeutics (CNTX), Telomir Pharmaceuticals, Inc. Common Stock (TELO), Tvardi Therapeutics (TVRD) and Marker Therapeutics (MRKR), listed from the closest match.

    Who is Transcode Therapeutics' biggest competitor?

    Grace Therapeutics (GRCE) is the largest of the similar companies at $38.08M; Plus Therapeutics (PSTV) is the closest match by business profile, size, sector and industry.

    How does RNAZ stock compare with its competitors?

    RNAZ's net margin is 0.0% against a peer median of 0.0%.

    Which of Transcode Therapeutics' competitors pays a higher dividend?

    Transcode Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Transcode Therapeutics bigger than its competitors?

    No. Transcode Therapeutics is 7th by market cap among the 13 companies on this page; the largest is Grace Therapeutics (GRCE) at $38.08M.